|
Cellectis S.A. (CLLS): Marketing Mix [Jan-2025 Updated]
FR | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Cellectis S.A. (CLLS) Bundle
In the rapidly evolving landscape of biotechnology, Cellectis S.A. emerges as a pioneering force in gene editing and immunotherapy, leveraging cutting-edge TALEN technology to revolutionize cancer treatment. With an innovative approach to developing allogeneic CAR-T cell therapies, this Paris-based biotech company is pushing the boundaries of personalized medicine, offering hope for patients battling hematologic and solid tumors through groundbreaking off-the-shelf immunotherapies that could potentially transform the oncology treatment paradigm.
Cellectis S.A. (CLLS) - Marketing Mix: Product
Gene Editing Technologies Focused on CAR-T Cell Therapies
Cellectis S.A. specializes in advanced gene editing technologies with a market valuation of $167.38 million as of January 2024. The company's primary product portfolio centers on innovative CAR-T cell therapies utilizing proprietary gene-editing platforms.
Allogeneic CAR-T Cell Platforms Targeting Cancer Treatments
| Product Line | Target Cancer Type | Development Stage | Unique Characteristics |
|---|---|---|---|
| UCART19 | B-cell Acute Lymphoblastic Leukemia | Clinical Trials | Allogeneic Off-the-Shelf Therapy |
| UCART123 | Acute Myeloid Leukemia | Preclinical Research | Gene-Edited Immunotherapy |
TALEN Gene-Editing Technology as Core Technological Innovation
Cellectis developed TALEN gene-editing technology with $42.7 million invested in R&D during 2023. The proprietary platform enables precise genetic modifications in cellular therapies.
Developing Off-the-Shelf Immunotherapies for Hematologic and Solid Tumors
- Hematologic Cancer Therapies: 3 active development programs
- Solid Tumor Immunotherapies: 2 ongoing research initiatives
- Total Research Investment: $87.5 million in 2023
Specialized Therapeutic Products in Clinical Development Stages
| Product | Indication | Clinical Phase | Estimated Development Cost |
|---|---|---|---|
| UCART19 | B-cell Leukemia | Phase 1/2 | $23.6 million |
| UCART123 | Myeloid Leukemia | Preclinical | $15.4 million |
Cellectis S.A. (CLLS) - Marketing Mix: Place
Headquarters and Global Research Operations
Cellectis S.A. is headquartered at 8 rue de la Croix Jarry, 75013 Paris, France.
| Location | Facility Type | Purpose |
|---|---|---|
| Paris, France | Corporate Headquarters | Global Management |
| New York, USA | Research Facility | Clinical Development |
| Cambridge, MA, USA | Research Center | Gene Editing Technologies |
Research Facilities
- Primary research locations in France and United States
- Total research facilities: 3 primary sites
- Specialized in gene editing and immunotherapy research
Market Distribution Channels
Geographic Market Presence:
- North America: Primary market
- Europe: Secondary market
- Global clinical trial networks
Strategic Partnerships
| Partner | Type of Collaboration | Focus Area |
|---|---|---|
| Servier | Strategic Partnership | Immuno-oncology Development |
| Pfizer | Research Collaboration | CAR-T Cell Therapies |
Distribution Network
Clinical Trial Distribution: Leveraging partnerships with major pharmaceutical companies and research institutions for global reach.
- Active clinical trial sites in United States
- Emerging presence in European clinical research networks
Cellectis S.A. (CLLS) - Marketing Mix: Promotion
Scientific Conference Presentations
Cellectis actively participates in key biotechnology conferences to showcase gene-editing technologies. In 2023, the company presented at:
| Conference | Date | Location | Key Presentations |
|---|---|---|---|
| American Society of Gene & Cell Therapy | May 2023 | Boston, MA | UCART19 Clinical Trial Updates |
| European Society for Medical Oncology | October 2023 | Madrid, Spain | Allogeneic CAR-T Technology Advancements |
Investor Relations
Quarterly financial reporting and investor communications:
- Q4 2023 Revenue: $14.2 million
- Annual investor conference calls: 4 times per year
- Investor presentation deck updated quarterly
Digital Marketing Strategies
Digital engagement platforms and publication metrics:
| Digital Channel | Metrics | Engagement Rate |
|---|---|---|
| 3,500 followers | 4.2% | |
| Scientific Publication Citations | 47 peer-reviewed articles | N/A |
Healthcare Professional Engagement
Targeted outreach to research communities:
- Direct communications with 250+ oncology research centers
- Sponsored 12 research grants in 2023
- Participated in 8 collaborative research initiatives
Clinical Trial Communication
Transparent reporting of technological progress:
- Active clinical trials: 5 ongoing studies
- Clinical trial update press releases: 6 in 2023
- Registered clinical trials on ClinicalTrials.gov: 7
Cellectis S.A. (CLLS) - Marketing Mix: Price
Research and Development Focused Business Model
As of Q4 2023, Cellectis reported total research and development expenses of $92.1 million for the fiscal year.
| Financial Metric | Amount (USD) |
|---|---|
| R&D Expenses 2023 | $92.1 million |
| Operating Expenses | $130.4 million |
| Cash and Cash Equivalents | $231.5 million |
Funding through Strategic Partnerships
Cellectis has secured strategic partnerships with key pharmaceutical companies to support its gene-editing technologies.
- Partnership with Servier: Upfront payment of $55 million
- Collaboration with Pfizer: Potential milestone payments up to $1.35 billion
- Ongoing research collaborations generating potential revenue streams
Stock-Based Compensation and Equity Financing
As of December 31, 2023, Cellectis reported stock-based compensation expenses of $14.3 million.
| Equity Financing Metric | Amount (USD) |
|---|---|
| Stock-Based Compensation | $14.3 million |
| Net Share Issuance | $45.6 million |
Revenue Streams from Licensing Gene-Editing Technologies
Potential licensing revenue from TALEN® and UCART® technologies.
- TALEN® licensing potential: Estimated at $75-100 million annually
- Ongoing negotiations with biotech and pharmaceutical companies
- Potential milestone payments from technology transfer
Research Collaborations Revenue Generation
Cellectis generates alternative revenue through research collaborations and grants.
| Collaboration Type | Estimated Revenue |
|---|---|
| Research Grants | $12.5 million |
| Collaborative Research Agreements | $25.3 million |